Recruiting

MRI Technique

Sponsor:

Memorial Sloan Kettering Cancer Center

Code:

NCT05559853

Conditions

Brain Metastases

Brain Metastases, Adult

Metastatic Brain Tumor

Metastatic Brain Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Interventions

CEST-MRF

Study Details

Brief summary:

The purpose of this study is to develop and test a new magnetic resonance imaging (MRI) technique to see if it can be used to tell the difference between tumor growth from worsening of cancer and growth from the effects of treatment in participants who have brain tumors treated with radiation therapy called stereotactic radiosurgery (SRS).

Conditions

Brain Metastases

Brain Metastases, Adult

Metastatic Brain Tumor

Metastatic Brain Cancer

Study ID

NCT05559853

Start date

Sep 22, 2022

Status verified date

Mar, 2026

Completion date

Sep 22, 2027

Anticipated

Primary completion date

Sep 22, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Inclusion Criteria:

Healthy volunteers \[for Study Aim 1 (SA1) and Study Aim 2 (SA2)\] will be entered into the study if they meet the following criteria:

  • Age ≥ 18 years
  • Able to understand and give informed consent
  • No known cancer diagnosis

Patients \[for Study Aim 1 (SA1)\] will be entered into the study if they meet the following criteria:

  • Age ≥ 18 years
  • Able to understand and give informed consent
  • At least one untreated brain metastasis > 1cm (e.g., an enhancing lesion in the brain of a patient with known systemic cancer determined likely to represent metastasis by neuroradiologist)

Patients \[for Study Aim 3 (SA3)\] will be entered into the study if they meet the following criteria:

  • Age ≥ 18 years
  • Able to understand and give informed consent
  • At least one untreated brain metastasis > 1cm (e.g., an enhancing lesion in the brain of a patient with known systemic cancer determined likely to represent metastasis by neuroradiologist)
  • Planned SRS treatment

Exclusion Criteria:

Healthy volunteers (SA1 \& SA2) and patients (SA1 \& SA3) exclusion criteria:

  • Pregnant or breastfeeding women
  • Pre-existing medical conditions, including the likelihood of developing seizures or claustrophobic reactions, and any greater than normal potential for cardiac arrest
  • Age < 18 years

Study Design

Enrollment

119 participants

Anticipated

Interventions and Outcome Measures

Arms

Participants with Brain Metastases

Participants will have at least one untreated brain metastasis > 1cm

Healthy participants

Participants will have no known cancer diagnosis. Volunteers enrolled on this protocol may undergo multiple MRI examinations periodically for studies of reproducibility.

Interventions

CEST-MRF

CEST-MRF enables accurate quantification of both proton exchange rates and volume fractions in a fraction of the time required by conventional pulse sequences will be developed and optimized.

Primary outcome measure

  • Change of Rapid chemical exchange saturation transfer (CEST) imaging with magnetic resonance fingerprinting (MRF)/CEST-MRF parameters with and without motion [ Time Frame: Up to 3 years ]

Central Contacts and Locations

Central contacts

Ouri Cohen, PhD

646-608-8259coheno1@mskcc.org

Nelson Moss, MD

212-639-7075mossn@mskcc.org

Locations

Memorial Sloan Kettering Cancer Center (All Protocol Activities)

Recruiting

New York, New York, United States, 10065

Contacts

Ouri Coheb, PhD

646-608-8259coheno1@mskcc.org

More Information

Sponsor

Memorial Sloan Kettering Cancer Center

Last update posted

Mar 6, 2026

Last verified

Mar, 2026

Keywords

  • Brain Metastases
  • Healthy Volunteers
  • metastatic brain tumor
  • metastatic brain cancer
  • Brain Metastases, Adult
  • MRI
  • untreated brain metastasis
  • CEST-MRF
  • chemical exchange saturation transfer magnetic resonance fingerprinting
  • 22-191
  • Memorial Sloan Kettering Cancer Center

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Memorial Sloan Kettering Cancer Center on 2026-03-06.